Cabot (NYSE:CBT) Given New $95.00 Price Target at Truist Financial

Cabot (NYSE:CBT) had its price objective decreased by investment analysts at Truist Financial from $100.00 to $95.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the specialty chemicals company’s stock. Truist Financial‘s price objective indicates a potential upside of 26.50% from the stock’s current price.

CBT has been the topic of a number of other reports. Weiss Ratings restated a “hold (c)” rating on shares of Cabot in a research note on Friday, August 21st. UBS Group reduced their price objective on shares of Cabot from $92.00 to $86.00 and set a “neutral” rating for the company in a research note on Monday, October 5th. JPMorgan Chase & Co. boosted their target price on shares of Cabot from $70.00 to $78.00 and gave the company an “underweight” rating in a report on Friday, August 7th. Finally, Wall Street Zen upgraded Cabot from a “hold” rating to a “buy” rating in a research report on Sunday, October 11th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $86.80.

Cabot Stock Performance

NYSE CBT traded up $3.10 during trading on Wednesday, hitting $75.10. 122,028 shares of the company’s stock traded hands, compared to its average volume of 455,000. The stock has a market capitalization of $3.88 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 8.91 and a beta of 0.83. Cabot has a 12-month low of $58.33 and a 12-month high of $94.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.97 and a current ratio of 1.47. The business has a 50 day moving average of $77.55 and a 200-day moving average of $79.52.

Cabot (NYSE:CBT) last issued its earnings results on Monday, November 2nd. The specialty chemicals company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.55 by $0.06. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $927.29 million. Cabot had a net margin of 5.69% and a return on equity of 19.79%. The company’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter last year, the business earned $1.70 earnings per share. As a group, equities research analysts anticipate that Cabot will post 7.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sean Keohane sold 134,895 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $85.00, for a total transaction of $11,466,075.00. Following the sale, the chief executive officer directly owned 404,134 shares in the company, valued at $34,351,390. This represents a 25.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 229,597 shares of company stock worth $19,646,746. 3.08% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CBT. Root Financial Partners LLC purchased a new position in Cabot in the 3rd quarter worth approximately $27,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Cabot in the 2nd quarter worth $33,000. Rockefeller Capital Management L.P. raised its position in shares of Cabot by 115.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,152 shares of the specialty chemicals company’s stock valued at $76,000 after buying an additional 617 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of Cabot during the 2nd quarter valued at $88,000. Finally, Parallel Advisors LLC raised its position in shares of Cabot by 10.5% during the 1st quarter. Parallel Advisors LLC now owns 1,843 shares of the specialty chemicals company’s stock valued at $139,000 after buying an additional 175 shares in the last quarter. 93.18% of the stock is currently owned by hedge funds and other institutional investors.

More Cabot News

Here are the key news stories impacting Cabot this week:

• Positive Sentiment: Fourth-quarter adjusted EPS was $1.61, above the $1.55 consensus, while revenue rose 12.2% year over year to $1.01 billion, exceeding estimates. Cabot beats Q4 earnings and revenue estimates
• Positive Sentiment: Battery Materials generated $43 million of full-year EBITDA, and Cabot secured a $50 million Department of Energy grant to expand U.S. production of battery conductive additives—potential support for longer-term growth. Cabot reports fourth-quarter and fiscal-year results
• Neutral Sentiment: The company plans $200 million to $230 million in fiscal 2027 capital spending. That investment could support growth, although it represents a substantial use of cash. Cabot forecasts fiscal 2027 EPS and capital spending
• Negative Sentiment: Fiscal 2027 adjusted EPS guidance of $6.15–$6.75 is below the $7.03 analyst consensus, signaling expectations for softer earnings ahead. Cabot forecasts fiscal 2027 EPS
• Negative Sentiment: Despite the quarterly beat, adjusted EPS declined from $1.70 a year earlier; full-year adjusted EPS fell to $6.42 from $7.25. Reports also pointed to weaker margins, tempering the strong revenue growth. Cabot falls despite beating estimates on weaker margins

About Cabot

Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company develops and manufactures materials used to improve the performance, durability, conductivity, color and purity of products across a range of industries.

Cabot’s products include carbon black used in tires, rubber goods, coatings, plastics and printing inks; specialty carbons and conductive materials for batteries and other applications; and specialty compounds and masterbatches.